secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001628280-23-033402
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter completes sale of BioPharma Solutions business for $4.25B in cash
------------------------------------------------------------------------

- Closed sale of Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH to Bamboo BidCo entities for $4.25B.
- Net pre-tax cash proceeds of approximately $3.96B received at closing.
- Company plans to use ~$3.4B of net after-tax proceeds to pay down debt through H1 2024.
- Prior full-year 2023 guidance scenario assuming no transaction is now withdrawn; only scenario with close remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/0001628280-23-033402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/bax-20230929.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-033402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer